ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
ADIA Nutrition Inc. (OTC Pink: ADIA) has launched a recruitment drive for sales representatives for its subsidiaries, Adia Med and Adia Labs. The initiative, announced on March 13, 2025, aims to expand the company's regenerative medicine and stem cell therapy presence nationwide.
Adia Med sales representatives will focus on establishing satellite locations by partnering with doctors, clinics, and medical spas, targeting regions with high demand for regenerative medicine. Meanwhile, Adia Labs representatives will promote 'Adia Vita,' a private-label umbilical cord stem cell product containing 100 million stem cells and 3 trillion exosomes per unit, for medical studies and research.
The company offers commission-based compensation and comprehensive training. Ideal candidates should possess strong communication skills, commitment to ethical practices, and knowledge or willingness to learn about regenerative medicine.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced strategic workforce expansions to enhance its operations and advance regenerative medicine capabilities. The company has hired a skilled intake nurse at their Winter Park Clinic who will manage patient intake, assist with assessments, and develop compliance standards for stem cell treatments across all Adia Med locations.
Additionally, the company has promoted a three-year intern to serve as CEO Larry Powalisz's aide, taking over marketing efforts, social media strategy, and various projects to allow the CEO to focus on broader company expansion initiatives.
These strategic hires follow ADIA Nutrition's recent achievements, including the profitable launch of the Adia Med Winter Park Clinic and plans for nationwide expansion. The new positions are expected to enhance operational efficiency, ensure scalable care standards, and strengthen the company's position in delivering regenerative therapies.
ADIA Nutrition Inc. (OTC Pink: ADIA) has filed trademark applications with the USPTO for its new product 'Adia Vita' and slogan 'The Platinum Standard in Stem Cell Therapy.' The company's new private-label umbilical cord stem cell product, Adia Vita, features third-party-verified content of 100 million stem cells and 3 trillion exosomes per unit.
The product is now available for purchase through Adia Labs to doctors and clinics for trials and research. According to CEO Larry Powalisz, these trademark filings aim to protect the brand from copycats and ensure product authenticity in the regenerative medicine market.
ADIA Nutrition (OTC Pink: ADIA) announces FDA registration acceptance for Adia Vita, its subsidiary Adia Labs' premier stem cell product. The product contains a minimum of 100 million viable cells and 3 trillion exosomes per unit.
The registration enables nationwide distribution to doctors and clinics, making advanced regenerative medicine more accessible. While typical stem cell therapies cost between $15,000-$35,000 per treatment, Adia Med aims to offer their superior product at a reduced price point.
The company is now actively expanding its reach across the United States, targeting healthcare providers and medical professionals to enhance patient care and support clinical research in various health conditions.
ADIA Nutrition Inc. (OTC Pink: ADIA) reports significant developments in February 2025, following a profitable January at its Winter Park Clinic. Key February milestones include: entering the $15.1B global stem cell market on February 3, appointing a PCAOB-registered accounting firm for OTCQB uplisting on February 5, and pledging to retire 25M undocumented shares (15% reduction) on February 11.
The company launched Adia Labs on February 20, introducing Adia Vita stem cell product. On February 24, they announced nationwide expansion through Medical Spa partnerships. By February 26, OTC Markets removed ADIA's shell risk designation, advancing their OTCQB uplisting goals.
The company's medical division, Adia Med, offers FDA-compliant stem cell treatments using umbilical cord products, targeting inflammation, autoimmune disorders, and orthopedic issues. Their Winter Park Clinic exceeded financial expectations in January 2025, covering all opening expenses with surplus revenue.
Adia Nutrition Inc. (OTC Pink: ADIA) has achieved a significant milestone by successfully removing its shell risk designation from OTC Markets, marking a important step toward uplisting from OTC Pink Sheets to the OTCQB Venture Market. This development enhances the company's market position and demonstrates its commitment to operational transparency.
The removal of the shell risk designation, a critical requirement for OTCQB status, was accomplished through close collaboration with OTC Markets. The company has been actively working to meet all uplisting criteria, including completing a comprehensive third-party audit.
CEO Larry Powalisz expressed enthusiasm about this achievement, indicating it will enable greater information sharing with investors. The OTCQB Venture Market is expected to provide enhanced transparency, liquidity, and investor trust, allowing Adia Nutrition to better showcase its stem cell therapies and nutritional products portfolio.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic nationwide expansion plan for Adia Med satellite locations through partnerships with premier Medical Spas. The initiative focuses on making their regenerative medicine treatments more accessible across the United States.
The expansion strategy involves collaborating with established Med Spas to offer Umbilical Cord Stem Cell therapies, stem cell injectables, and other regenerative solutions. The company will implement a phased approach, starting with pilot programs in major cities and affluent suburbs with health-conscious demographics.
The business model includes multiple revenue streams through service fees, royalties, and potential equity interests. ADIA will provide comprehensive training and quality control measures to maintain consistent treatment standards across all locations. CEO Larry Powalisz emphasized that successful Med Spas will benefit from a generous commission structure and increased patient base.
ADIA Nutrition (OTC Pink: ADIA) has launched Adia Labs , a new division focused on regenerative medicine. The company introduces two key products: AdiaVita, a private-label umbilical cord stem cell product guaranteeing 100 million viable cells and 3 trillion exosomes per unit, and AdiaLink, an upcoming product offering 3.5 trillion exosomes per unit.
The launch was enabled through a partnership with an FDA-approved laboratory, allowing ADIA to offer these products under its own brand. The products are specifically designed for clinical research, studies, and trials, targeting a potential client base of over one million doctors and clinics nationwide.
These products aim to address various conditions, including autoimmune diseases, degenerative disorders, and injury recovery, focusing on non-invasive biological treatments. Doctors and clinics can purchase these products through adialabs.com.
Adia (ADIA) has announced a strategic partnership with an FDA-approved laboratory specializing in regenerative medicine. The collaboration focuses on providing high-quality umbilical cord stem cell and exosome products. The lab's products feature 100 million umbilical cord stem cells and 3 trillion exosomes per dose.
The partnership highlights several key attributes: FDA approval ensuring safety and quality protocols for biologics, third-party verification for product quality, minimal manipulation techniques to preserve therapeutic properties, and research excellence in identifying optimal umbilical cord stem cell sources. The products are intended for various therapeutic applications, including orthopedics, neurology, and dermatology.
The company aims to distribute these advanced products for clinical trials, therapeutic use, and preventive medicine applications, particularly in anti-aging and wellness treatments.
Adia Med, the medical division of Adia Nutrition (OTC Pink: ADIA), is pursuing registration with Florida's Agency for Health Care Administration (AHCA) to accept private insurance for its stem cell therapies. This initiative aims to expand access to their Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and injectable stem cell treatments.
Currently operating on an out-of-pocket payment model, the company aims to reduce financial barriers through insurance coverage. The company has engaged specialized consultants for AHCA registration and financial documentation. Multiple potential clients have already received preapproval from private insurers for both HSCT and injectable stem cell therapies, indicating growing acceptance of these treatments in the insurance industry.